The shareholders in the research company Stayble Therapeutics are called to an extraordinary general meeting, which also serves as the first control meeting, on Thursday, May 7 in Gothenburg.
The company has, as previously announced, prepared a control balance sheet, which has been reviewed by the company’s auditor. The control balance sheet shows that equity is less than half of the registered share capital.
The board has considered possible financing alternatives but assessed that there are no conditions to ensure continued operations. The board therefore proposes that the meeting resolve on voluntary liquidation of the company and that the company’s assets be sold to the highest bidder.
The board proposes…